Arbutus Biopharma (ABUS) Tops Q2 EPS by 1c
Tweet
Share
E-mailGet Alerts ABUS Hot Sheet
Join SI Premium – FREE
Arbutus Biopharma (NASDAQ: ABUS) reported Q2 EPS of ($0.10), $0.01 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $4.65 million versus the consensus estimate of $6.18 million.
For earnings history and earnings-related data on Arbutus Biopharma (ABUS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- William Blair Downgrades On Holding AG (ONON) to Market Perform
- LENZ Therapeutics, Inc. (LENZ) Tops Q2 EPS by 5c
- CoreWeave, Inc. (CRWV) Tops Q2 EPS by 27c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
